[1] WHO. Global tuberculosis report 2021. WHO. 2021.
[2] Chinese Center for Disease Control and Prevention. Working plan for the prevention and control of MDR-TB. 2011.
[3] World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment. World Health Organization. 2020.
[4] Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition). Chin J Antituberc, 2021; 43, 859−66. (In Chinese
[5] Tuberculosis Prevention and Control Center of China Center for Disease Control and Prevention. Technical Guidelines for tuberculosis prevention and control in China (2021 edition). People's Medical Publishing House. 2022. (In Chinese)
[6] Website CGP. Procurement tender announcement of anti-tuberculosis drugs in Jiangsu province 2022. 2022.
[7] Wolfson LJ, Walker A, Hettle R, et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One, 2015; 10, e0120763. doi:  10.1371/journal.pone.0120763
[8] Wolfson LJ, Gibbert J, Wirth D, et al. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany. Eur Respir J, 2015; 46, 1826−9. doi:  10.1183/13993003.00811-2015
[9] Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res, 2017; 17, 182. doi:  10.1186/s12913-017-2118-2
[10] Vassall A. Cost-effectiveness of introducing bedaquiline in MDR-TB regimens: an exploratory analysis. WHO. 2013.
[11] Schnippel K, Firnhaber C, Conradie F, et al. Incremental cost effectiveness of bedaquiline for the treatment of rifampicin-resistant tuberculosis in South Africa: model-based analysis. Appl Health Econ Health Policy, 2018; 16, 43−54. doi:  10.1007/s40258-017-0352-8
[12] Park HY, Ku HM, Sohn HS, et al. Cost-effectiveness of bedaquiline for the treatment of multidrug-resistant tuberculosis in the republic of Korea. Clin Ther, 2016; 38, 655−67.e2. doi:  10.1016/j.clinthera.2016.01.023
[13] Lu XY, Smare C, Kambili C, et al. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC Health Serv Res, 2017; 17, 87. doi:  10.1186/s12913-016-1931-3
[14] Fan QQ, Ming WK, Yip WY, et al. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. Int J Infect Dis, 2019; 78, 44−9. doi:  10.1016/j.ijid.2018.10.007
[15] Codecasa LR, Toumi M, D’Ausilio A, et al. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. J Mark Access Health Policy, 2017; 5, 1283105. doi:  10.1080/20016689.2017.1283105
[16] Chinese Center for Disease Control and Prevention. Costing of diagnosis and treatment of TB. 2021.
[17] Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics, 2009; 27, 903−17. doi:  10.2165/10899580-000000000-00000
[18] National Bureau of Statistics. Statistical communiqué of the People's Republic of China on the 2020 national economic and social development. China Statistics Press. 2021. (In Chinese)
[19] Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force–3. Med Decis Making, 2012; 32, 690−700. doi:  10.1177/0272989X12455463
[20] Chinese Center for Disease Control and Prevention. The global fund MDR-TB control program in China: experience and accompliment. People’s Medical Publishing House. 2015. (In Chinese)
[21] Zhang Y. The evaluation of the mid-term efficacy of Global Fund multi-drug resistant tuberculosis (MDR-TB) Project in Dalian. Dalian Medical University. 2016. (In Chinese)
[22] Hao XH, Yao L, Tang SJ, et al. A cohort study on the outcome of multidrug-resistant tuberculosis among newly diagnosed cases. Chin J Infect Dis, 2012; 30, 157−61.
[23] Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2021; 27, 597−602. doi:  10.1016/j.cmi.2020.06.004
[24] Jones E, Epstein D, García-Mochón L. A procedure for deriving formulas to convert transition rates to probabilities for multistate Markov models. Med Decis Making, 2017; 37, 779−89. doi:  10.1177/0272989X17696997
[25] FDA. BRIEFING PACKAGE (NDA 204-384). http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm293600.htm. [2023-3-25].
[26] WHO. Drug-resistant TB treatment. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-diagnosis-treatment/3-4-drug-resistant-tb-treatment. [2023-3-25].
[27] Liu CH, Li L, Chen Z, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One, 2011; 6, e19399. doi:  10.1371/journal.pone.0019399
[28] Kittikraisak W, Kingkaew P, Teerawattananon Y, et al. Health related quality of life among patients with tuberculosis and HIV in Thailand. PLoS One, 2012; 7, e29775. doi:  10.1371/journal.pone.0029775
[29] Liu GE. China guidelines for pharmacoeconomic evaluations 2020. China Market Press. 2020. (In Chinese)
[30] National Health Commission. Action Plan for Stopping TB (2019-2022). https://www.gov.cn/gongbao/content/2019/content_5437149. [2023-3-25]. (In Chinese)
[31] Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health, 2010; 13, 592−600. doi:  10.1111/j.1524-4733.2010.00733.x
[32] Dai ZL, Wong IOL, Xie C, et al. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China. Clin Microbiol Infect, 2022; 28, 300.e1−8. doi:  10.1016/j.cmi.2021.06.024
[33] National Bureau of Statistics. Gansu Province 2020 annual data. http://www.stats.gov.cn/sj/ndsj/2020/indexch.htm. [2023-3-25]. (In Chinese)
[34] Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis, 2008; 46, 1844−51. doi:  10.1086/588292